Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) has issued an update.
Shanghai Henlius Biotech, Inc. announced the approval of phase 2/3 clinical trials for its HLX22 and HLX87 combination therapy for HER2-positive breast cancer by the National Medical Products Administration. This development signifies a significant step in the company’s efforts to advance its cancer treatment portfolio, potentially enhancing its market position in oncology therapeutics.
The most recent analyst rating on (HK:2696) stock is a Hold with a HK$74.00 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on developing innovative biologic drugs. The company specializes in monoclonal antibodies and antibody-drug conjugates, targeting various cancers including breast and gastric cancer.
Average Trading Volume: 1,380,812
Technical Sentiment Signal: Buy
Current Market Cap: HK$36.71B
Find detailed analytics on 2696 stock on TipRanks’ Stock Analysis page.